Pharmaceuticals company Caplin Point Laboratories announced Q3FY26 results Revenue: Rs 542.8 crore against Rs 493 crore during Q3FY25, change 10%. EBITDA: Rs 223.4 crore against Rs 193.7 crore during Q3FY25, change 15%. EBITDA Margin: 38.7% for Q3FY26. PBT: Rs 203.9 crore against Rs 177.3 crore during Q3FY25, change 15%. PBT Margin: 35.4% for Q3FY26. PAT: Rs 165.9 crore against Rs 140.1 crore during Q3FY25, change 18%. PAT Margin: 28.8% for Q3FY26. C.C. Paarthipan, Chairman, said: Our performance in Q3FY26 and 9MFY26 reflects far more than financial outcomes - it reflects the quiet compounding of a long-term strategy built on being different from others. We have sustained our strong margins, expanded profitability, and delivered robust cash generation, all while continuing to invest heavily in capacity, technology, people and future platforms. This balance between growth and prudence remains central to how we think about building enduring value. In Emerging Markets, our end-to-end business model continues to create a powerful competitive moat, as we create enriching value on both sides by catering to the bottom of the pyramid. By keeping products closer to customers, expanding local presence, and broadening our portfolio through internal development and global partnerships, we are steadily deepening relevance in markets that value reliability, affordability, and long-term commitment. Our progress in Latin America, the scaling of GLP-1 products, the acceleration of our “China 2.0” strategy, and our investments in oncology and APIs reinforce our belief that resilience is built through thoughtful vertical integration and geographic diversification. In the US and other regulated markets, Caplin Steriles continues to move up the complexity curve — combining strong compliance, first-cycle approvals, advanced drug-delivery platforms, and increasing automation. The early success of our US front end, along with investments in pre-filled syringes, BFS, and “Visual Integration” project positions us well for the next phase of growth. As we look ahead, we remain guided by a simple principle: build compliance through automation, expand capabilities ahead of demand, and grow businesses that can compound sustainably. With a strong balance sheet, a deep pipeline, and a clear strategic roadmap, we are confident in our ability to create lasting value for patients, partners, and shareholders alike. Result PDF